Core Points - The company ensures that the content of the quarterly report is true, accurate, and complete, with no false records or misleading statements [2][8] - The third-quarter financial report has not been audited [3][7] Financial Data - The company does not require retrospective adjustments or restatements of previous annual accounting data [3] - There are no non-recurring profit and loss items applicable for the reporting period [3][4] - The company confirms that there are no changes in major accounting data and financial indicators that require explanation [5] Shareholder Information - The total number of ordinary shareholders and the number of preferred shareholders have changed due to stock issuance and other reasons [5] - There are no changes in the top ten shareholders or the top ten unrestricted circulating shareholders due to stock lending activities [5][6] Board Meeting - The company's board meeting was held on October 27, 2025, with all seven directors present, complying with legal and regulatory requirements [9][10] - The board approved the third-quarter report and the appointment of a new member to the strategic committee [10][11]

Core Viewpoint - 易瑞生物 reported a significant increase in both revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 186 million yuan, representing a year-on-year growth of 17.45% [1] - The net profit attributable to shareholders was 18.02 million yuan, showing a remarkable year-on-year increase of 362.49% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.73 million yuan, reflecting a year-on-year growth of 137.78% [1] - Basic earnings per share were reported at 0.0449 yuan [1]

Core Points - The company, Easybio (300942), announced the appointment of Mo Qiuhua as a member of the Strategic Committee of the third board of directors [1] Group 1 - The board of directors approved the election of Mo Qiuhua as a representative director [1]

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于补选第三届董事会战略委员会委员的公告 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第三届董事会第十四次会议审议通过了《关于补选第三届董事会战略 委员会委员的议案》。 深圳市易瑞生物技术股份有限公司 董事会 2025 年 10 月 27 日 鉴于公司规范运作需要，董事会同意补选职工代表董事莫秋华先生为公司第 三届董事会战略委员会委员，任期自本次董事会审议通过之日起至第三届董事会 届满之日止。 本次补选完成后，公司第三届董事会战略委员会成员为肖昭理（主任委员）、 莫秋华、李文天。 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2025年10月27 日（星期一）在深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园公 司会议室以现场与通讯相结合的方式召开了第三届董事会第十四次会议。本次会 议通知已于2025年10月24日以电子邮件、微信等方式送达全体董事。本次会议由 董事长肖昭理先生召集并主持，本次会议应出席董事7人，实际出席董事7人（现 场出席董事4人，通讯出席董事3人），公司全体高级管理人员列席了本次会议。 本次会议的召集、通知、召开和表决程序均符合《公司法》等有关法律、行政法 规、规范性文件、部门规章及《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 经与会董事审议并以书面记名投票的方式 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥76,346,216.83, representing a 40.34% increase year-over-year[5] - Net profit attributable to shareholders was ¥15,683,546.58, a significant increase of 187.43% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.0391, reflecting a growth of 187.50% year-over-year[5] - Total operating revenue increased to ¥185,633,642.05, up 17.5% from ¥158,047,893.25 in the previous period[18] - Net profit for the period reached ¥18,807,119.87, significantly higher than ¥2,987,228.32 from the previous period, marking a 529.5% increase[19] - Earnings per share (EPS) improved to ¥0.0449, compared to ¥0.0097 in the previous period, representing a 363.9% increase[20] - The company reported a total comprehensive income of ¥18,698,893.43, compared to ¥2,922,366.69 in the previous period, reflecting a substantial increase[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,481,560,034.85, an increase of 1.67% from the previous year[5] - Total current assets at the end of the reporting period amount to 775,373,728.96 CNY, an increase from 751,616,151.89 CNY at the beginning of the period[15] - Total non-current assets are 706,186,305.89 CNY, slightly up from 705,549,784.03 CNY[15] - Total liabilities decreased to ¥571,208,353.56 from ¥586,923,364.94, a reduction of 2.4%[16] - Total equity attributable to shareholders increased to ¥908,090,377.01 from ¥869,005,338.22, a growth of 4.5%[16] Cash Flow - Cash flow from operating activities showed a decline of 51.16% year-to-date, totaling ¥7,828,976.36[5] - Cash inflow from operating activities totaled ¥206,284,991.21, an increase from ¥183,656,359.44, reflecting a growth of 12.2%[21] - The net cash flow from operating activities decreased to $7,828,976.36 from $16,031,477.88, representing a decline of approximately 51.1% year-over-year[22] - The net cash flow from investing activities improved significantly to $154,991,728.36 compared to a negative cash flow of $315,617,017.17 in the previous period[22] - Cash and cash equivalents at the end of the period increased to $398,991,770.35 from $212,754,799.40, marking a net increase of $141,859,810.93[22] - The company reported a cash inflow of $26,928,827.62 from financing activities, down from $52,000,000.00, a decrease of approximately 48.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,436[11] - The largest shareholder, Yirui (Hainan) Venture Capital Co., Ltd., holds 32.68% of shares, totaling 132,369,971 shares[11] - The second-largest shareholder, Zhu Hai, owns 14.85% of shares, amounting to 60,171,195 shares[11] Operational Costs and Expenses - Total operating costs rose to ¥181,665,643.90, compared to ¥158,868,141.37, reflecting a 14.4% increase[18] - Research and development expenses were ¥30,819,335.83, up from ¥28,803,950.34, indicating a 7.0% increase[19] Cash Management - The cash received from investment activities increased by 33.87%, totaling ¥686,213,774.35, primarily due to the redemption of financial products[9] - The company experienced a 70.03% decrease in cash paid for the acquisition of fixed assets, totaling ¥32,164,358.98[9] - Total cash outflow from financing activities was $51,094,548.12, up from $20,326,577.48, indicating a significant increase in financing costs[22] - The cash paid for operating activities totaled $198,456,014.85, an increase from $167,624,881.56, indicating a rise of about 18.3%[22] - The cash received from investment recoveries was $20,598,934.48, down from $34,161,616.16, reflecting a decline of about 39.5%[22] - The company’s total cash outflow for investing activities was $586,485,714.74, a decrease from $864,388,277.17, indicating a reduction of approximately 32.2%[22] - The impact of exchange rate changes on cash and cash equivalents was positive at $3,204,826.71, compared to a negative impact of $932,712.50 in the previous period[22]

Core Insights - The company reported a third-quarter revenue of 76.3462 million yuan, representing a year-on-year growth of 40.34% [1] - The net profit for the third quarter was 15.6835 million yuan, showing a significant year-on-year increase of 187.43% [1] - For the first three quarters, the total revenue reached 186 million yuan, which is a year-on-year growth of 17.45% [1] - The net profit for the first three quarters was 18.023 million yuan, reflecting a substantial year-on-year increase of 362.49% [1]

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于近日收到公司首 次公开发行股票并在创业板上市以及向不特定对象发行可转换公司债券项目的 保荐机构东兴证券股份有限公司（以下简称"东兴证券"）出具的《关于更换持 续督导保荐代表人的通知函》，获悉东兴证券原委派的保荐代表人周磊先生因工 作变动离职，不再继续担任公司持续督导保荐代表人。为保证公司持续督导工作 的有序进行，东兴证券委派吴时迪先生（简历见附件）接替周磊先生担任公司持 续督导保荐代表人，继续履行持续督导职责。 本次保荐代表人更换后，负责公司持续督导工作的保荐代表人为林苏钦女士 和吴时迪先生，持续督导期限直至持续督导义务结束为止。 深圳市易瑞生物技术股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司 董事会 2025 年 10 月 15 日 1 附件 ...

Core Viewpoint - The company, EasyReel Bio, is undergoing significant changes due to frequent shareholder reductions and a strategic shift away from its in vitro diagnostic business, which has seen a drastic decline in demand, particularly for respiratory infectious disease testing products [2][7]. Shareholder Reduction - EasyReel Bio's controlling shareholder, EasyReel (Hainan) Venture Capital Co., Ltd., plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital [3] - Other shareholders, EasyDarui and EasyKairui, also plan to reduce their holdings by 288,500 shares (0.07%) and 341,800 shares (0.08%), respectively [3] - If the maximum reduction occurs, the total cash outflow for the shareholders could reach approximately 1.23 million yuan based on the closing price of 10.12 yuan per share on October 13 [3] Business Performance and Strategy Shift - EasyReel Bio's revenue has significantly declined in 2023, with total revenue of 253 million yuan, a year-on-year decrease of 63.01%, and a net loss of 185 million yuan [7] - The in vitro diagnostic business, which once contributed up to 70% of revenue, has seen a drastic reduction in income, dropping to 47.7 million yuan in 2023, a 90.45% decline [7][8] - The company has shifted its focus back to food safety rapid testing and animal diagnostics, with food safety revenue showing a slight increase of 5.29% in 2024 [8] Historical Financial Performance - From 2020 to 2022, EasyReel Bio's revenue grew significantly due to the COVID-19 pandemic, with total revenues of 259 million yuan, 598 million yuan, and 687 million yuan, respectively [6] - The in vitro diagnostic business revenue during this period surged, reaching 499 million yuan in 2022, accounting for 72.71% of total revenue [6] Future Outlook - The company plans to completely phase out its in vitro diagnostic products by 2025, focusing solely on food safety and animal diagnostics [7][8] - Despite a strategic pivot, the company has faced challenges, with non-recurring net profits remaining negative for two and a half years [8][9]